Salvia divinorum and salvinorin A: An update on pharmacology and analytical methodology

Planta Medica

Volumn 73, Issue 10, 2007, Pages 1039-1046

  Grundmann, Oliver ^a   Phipps, Stephen M ^a   Zadezensky, Immo ^a   Butterweck, Veronika ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Depression; Lamiaceae; Opioid antagonist; Pharmacokinetics; Pharmacology; Salvia divinorum; Salvinorin A; Toxicology

Indexed keywords

DITERPENE; OPIATE ANTAGONIST; PLANT EXTRACT; SALVIA DIVINORUM EXTRACT; SALVINORIN A; UNCLASSIFIED DRUG;

CENTRAL NERVOUS SYSTEM DISEASE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESEARCH; HUMAN; REVIEW;

ANTIDEPRESSIVE AGENTS; DITERPENES; DITERPENES, CLERODANE; HUMANS; PHYTOTHERAPY; RECEPTORS, OPIOID, KAPPA; SALVIA;

ANIMALIA; LAMIACEAE; SALVIA DIVINORUM;

EID: 34548652748     PISSN: 00320943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-981566     Document Type: Review

References (57)

1. Epling C, Jativa MC. A new species of Salvia from Mexico. Bot Mus Leafl Harv Univ 1962; 20: 75-6.
2. Sheffler DJ, Roth BL. Salvinorin A: the "magic mint" hallucinogen finds a molecular target in the kappa opioid receptor. Trends Pharmacol Sci 2003; 24: 107-9.
3. Siebert DJ. Salvia divinorum and salvinorin A: new pharmacologic findings. J Ethnopharmacol 1994; 43: 53-6.
4. Valdes LJ 3rd. Salvia divinorum and the unique diterpene hallucinogen, Salvinorin (divinorin) A. J Psychoactive Drugs 1994; 26: 277-83.
5. Giroud C, Felber F, Augsburger M, Horisberger B, Rivier L, Mangin P. Salvia divinorum: an hallucinogenic mint which might become a new recreational drug in Switzerland. Forensic Sci Int 2000; 112: 143-50.
6. Halpern JH. Hallucinogens and dissociative agents naturally growing in the United States. Pharmacol Ther 2004; 102: 131-8.
7. Prisinzano TE. Psychopharmacology of the hallucinogenic sage Salvia divinorum. Life Sci 2005; 78: 527-31.
8. Bertea CM, Luciano P, Bossi S, Leoni F, Baiocchi C, Medana C et al. PCR and PCR-RFLP of the 5S-rRNA-NTS region and salvinorin A analyses for the rapid and unequivocal determination of Salvia divinorum. Phytochemistry 2006; 67: 371-8.
9. Imanshahidi M, Hosseinzadeh H. The pharmacological effects of Salvia species on the central nervous system. Phytother Res 2006; 20: 427-37.
10. Roth BL, Lopez E, Beischel S, Westkaemper RB, Evans JM. Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: a novel approach for CNS drug discovery. Pharmacol Ther 2004; 102: 99-110.
11. O'Connor KA, Roth BL. Screening the receptorome for plant-based psychoactive compounds. Life Sci 2005; 78: 506-11.
12. Yan F, Mosier PD, Westkaemper RB, Stewart J, Zjawiony JK, Vortherms TA et al. Identification of the molecular mechanisms by which the diterpenoid salvinorin A binds to kappa-opioid receptors. Biochemistry 2005; 44: 8643-51.
13. Butelman ER, Harris TJ, Kreek MJ. The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys. Psychopharmacology (Berl) 2004; 172: 220-4.
14. Butelman ER, Mandau M, Tidgewell K, Prisinzano TE, Yuferov V, Kreek MJ. Effects of salvinorin A, a {kappa}-opioid hallucinogen, on a neuroendocrine biomarker assay in non-human primates with high {kappa}-receptor homology to humans. J Pharmacol Exp Ther 2007; 320: 300-6.
15. Todtenkopf MS, Marcus JF, Portoghese PS, Carlezon WA Jr. Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats. Psychopharmacology (Berl) 2004; 172: 463-70.
16. Mague SD, Pliakas AM, Todtenkopf MS, Tomasiewicz HC, Zhang Y, Stevens WCJr. et al. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther 2003; 305: 323-30.
17. Thiebot MH, Martin P, Puech AJ. Animal behavioural studies in the evaluation of antidepressant drugs. Br J Psychiatry Suppl; 1992: 44-50.
18. Carlezon WA Jr, Beguin C, DiNieri JA, Baumann MH, Richards MR, Todtenkopf MS et al. Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther 2006; 316: 440-7.
19. Lukas G, Brindle SD, Greengard P. The route of absorption of intraperitoneally administered compounds. J Pharmacol Exp Ther 1971; 178: 562-4.
20. Hanes KR. Antidepressant effects of the herb Salvia divinorum: a case report. J Clin Psychopharmacol 2001; 21: 634-5.
21. Munro TA, Goetchius GW, Roth BL, Vortherms TA, Rizzacasa MA. Autoxidation of salvinorin A under basic conditions. J Org Chem 2005; 70: 10057-61.
22. Lee DY, Ma Z, Liu-Chen LY, Wang Y, Chen Y, Carlezon WAJr et al. New neoclerodane diterpenoids isolated from the leaves of Salvia divinorum and their binding affinities for human kappa opioid receptors. Bioorg Med Chem 2005; 13: 5635-9.
23. Kawadias D, Monschein V, Sand P, Riederer P, Schreier P. Constituents of sage (Salvia officinalis) with in vitro affinity to human brain benzodiazepine receptor. Planta Med 2003; 69: 113-7.
24. Beguin C, Richards MR, Wang Y, Chen Y, Liu-Chen LY, Ma Z et al. Synthesis and in vitro pharmacological evaluation of salvinorin A analogues modified at C(2). Bioorg Med Chem Lett 2005; 15: 2761-5.
25. Zhang Y, Butelman ER, Schlussman SD, Ho A, Kreek MJ. Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors. Psychopharmacology (Berl) 2005; 179: 551-8.
26. Fantegrossi WE, Kugle KM, Valdes LJ 3rd, Koreeda M, Woods JH. Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse. Behav Pharmacol 2005; 16: 627-33.
27. Vonvoigtlander PF, Lahti RA, Ludens JH. U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist. J Pharmacol Exp Ther 1983; 224: 7-12.
28. Wang Y, Tang K, Inan S, Siebert D, Holzgrabe U, Lee DY et al. Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo. J Pharmacol Exp Ther 2005; 312: 220-30.
29. McCurdy CR, Sufka KJ, Smith GH, Warnick JE, Nieto MJ. Antinociceptive profile of salvinorin A, a structurally unique kappa opioid receptor agonist. Pharmacol Biochem Behav 2006; 83: 109-13.
30. John TF, French LG, Erlichman JS. The antinociceptive effect of salvinorin A in mice. Eur J Pharmacol 2006; 545: 129-33.
31. Capasso R, Borrelli F, Capasso F, Siebert DJ, Stewart DJ, Zjawiony JK et al. The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A inhibit enteric cholinergic transmission in the guinea-pig ileum. Neurogastroenterol Motil 2006; 18: 69-75.
32. Valdes LJ 3rd, Chang HM, Visger DC, Koreeda M. Salvinorin C, a new neoclerodane diterpene from a bioactive fraction of the hallucinogenic Mexican mint Salvia divinorum. Org Lett 2001; 3: 3935-7.
33. Munro TA, Rizzacasa MA. Salvinorins D-F, new neoclerodane diterpenoids from Salvia divinorum, and an improved method for the isolation of salvinorin A. J Nat Prod 2003; 66: 703-5.
34. Shirota O, Nagamatsu K, Sekita S. Neo-clerodane diterpenes from the hallucinogenic sage Salvia divinorum. J Nat Prod 2006; 69: 1782-6.
35. Bigham AK, Munro TA, Rizzacasa MA, Robins-Browne RM. Divinatorins A-C, new neoclerodane diterpenoids from the controlled sage Salvia divinorum. J Nat Prod 2003; 66: 1242-4.
36. Harding WW, Tidgewell K, Schmidt M, Shah K, Dersch CM, Snyder J et al. Salvinicins A and B, new neoclerodane diterpenes from Salvia divinorum. Org Lett 2005; 7: 3017-20.
37. Munro TA, Rizzacasa MA, Roth BL, Toth BA, Yan F. Studies toward the pharmacophore of salvinorin A, a potent kappa opioid receptor agonist. J Med Chem 2005; 48: 345-8.
38. Harding WW, Schmidt M, Tidgewell K, Kannan P, Holden KG, Dersch CM et al. Synthetic studies of neoclerodane diterpenes from Salvia divinorum: selective modification of the furan ring. Bioorg Med Chem Lett 2006; 16: 3170-4.
39. Chavkin C, Sud S, Jin W, Stewart J, Zjawiony JK, Siebert DJ et al. Salvinorin A, an active component of the hallucinogenic sage Salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations. J Pharmacol Exp Ther 2004; 308: 1197-203.
40. Tidgewell K, Harding WW, Lozama A, Cobb H, Shah K, Kannan P et al. Synthesis of salvinorin A analogues as opioid receptor probes. J Nat Prod 2006; 69: 914-8.
41. Wasson RG. A new Mexican psychotropic drug from the mint family. Bot Mus Leafl Harv Univ 1962; 20: 163-93.
42. Valdes LJ 3rd, Diaz JL, Paul AG. Ethnopharmacology of ska Maria Pastora (Salvia divinorum, Epling and Jativa-M.). J Ethnopharmacol 1983; 7: 287-312.
43. Schmidt MD, Schmidt MS, Butelman ER, Harding WW, Tidgewell K, Murry DJ et al. Pharmacokinetics of the plant-derived kappa-opioid hallucinogen salvinorin A in nonhuman primates. Synapse 2005; 58: 208-10.
44. Negus SS, Wurrey BA, Mello NK. Sex differences in thermal nociception and prostaglandin-induced thermal hypersensitivity in rhesus monkeys. J Pain 2004; 5: 92-103.
45. Butterweck V, Lieflander-Wulf U, Winterhoff H, Nahrstedt A. Plasma levels of hypericin in presence of procyanidin B2 and hyperoside: a pharmacokinetic study in rats. Planta Med 2003; 69: 189-92.
46. Rold JF. Mushroom madness. Psychoactive fungi and the risk of fatal poisoning. Postgrad Med 1986; 79: 217-8.
47. Scallet AC, Lipe GW, Ali SF, Holson RR, Frith CH, Slikker W Jr. Neuropathological evaluation by combined immunohistochemistry and degeneration-specific methods: application to methylenedioxymethamphetamine. Neurotoxicology 1988; 9: 529-37.
48. Tiongson J, Salen P. Mass ingestion of Jimson Weed by eleven teenagers. Del Med J 1998; 70: 471-6.
49. Mowry M, Mosher M, Briner W. Acute physiologic and chronic histologic changes in rats and mice exposed to the unique hallucinogen salvinorin A. J Psychoactive Drugs 2003; 35: 379-82.
50. Schaper D. Legal, herbal hallucinogenic draws teens, critics. In: All things considered. United States of America: National Public Radio; 2006: 7 minutes 25 seconds..
51. 5' Bucheler R, Gleiter CH, Schwoerer P, Gaertner I. Use of nonprohibited hallucinogenic plants: increasing relevance for public health. A case report and literature review on the consumption of Salvia divinorum (Diviner's Sage)? Pharmacopsychiatry 2005; 38: 1-5.
52. Schmidt MS, Prisinzano TE, Tidgewell K, Harding W, Butelman ER, Kreek MJ et al. Determination of salvinorin A in body fluids by high performance liquid chromatography-atmospheric pressure chemical ionization. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 818: 221-5.
53. Pichini S, Abanades S, Farre M, Pellegrini M, Marchei E, Pacifici R et al. Quantification of the plant-derived hallucinogen Salvinorin A in conventional and non-conventional biological fluids by gas chromatography/mass spectrometry after Salvia divinorum smoking. Rapid Commun Mass Spectrom 2005; 19: 1649-56.
54. Medana C, Massolino C, Pazzi M, Baiocchi C. Determination of salvinorins and divinatorins in Salvia divinorum leaves by liquid chromatography/multistage mass spectrometry. Rapid Commun Mass Spectrom 2006; 20: 131-6.
55. Wolowich WR, Perkins AM, Cienki JJ. Analysis of the psychoactive terpenoid salvinorin A content in five Salvia divinorum herbal products. Pharmacotherapy 2006; 26: 1268-72.
56. Gruber JW, Siebert DJ, Der Marderosian AH, Hock RS. High performance liquid chromatographic quantification of salvinorin A from tissues of Salvia divinorum Epling & Ja'tiva-M. Phytochem Anal 1999; 10: 22-5.
57. Siebert DJ. Localization of salvinorin A and related compounds in glandular trichomes of the psychoactive sage, Salvia divinorum. Ann Bot (Lond) 2004; 93: 763-71.